And yet one more Release:
Pathobiotek Diagnostics Retains OTC Financial Network to Lead Comprehensive Investor
Relations Campaign
HOUSTON--(BW HealthWire)--March 9, 2000--Pathobiotek Diagnostics Inc. (PDI) (OTC BB: PBTK), a developer of products for the diagnosis and evaluation
of treatment for multiple sclerosis (MS) and other immune disorders, today announced that it has selected OTC Financial Network, a division of National Financial
Communications Corp. of Needham, Massachusetts, to direct its financial communications and shareholder relations campaign.
The majority of Pathobiotek's research is focused on developing new and innovative MS diagnostics applications and products based on Luey technology platform.
Luey, a human microorganism characterized by scientist at PDI, has been the center of new product development with the primary effort devoted to products with
near-term market potential.
Pathobiotek Diagnostics Chairman and Chief Executive Officer Robert C. Simpson commented, "This platform provides the potential for many new products, as well
as additional applications for our existing products. PDI produces an increasing number of products available for licensing and the time is right to team up with an
experienced investor relations firm such as National Financial Communications in order to introduce PBTK to investors and the wider public."
Geoffrey Eiten, president of National Financial Communications, added, "There are over 300,000 people in the U.S. and over a million people in the world, who
suffer from MS and related diseases. Pathobiotek's revolutionary products are so new and innovative that it is expected that the current, conventional methodologies
for treating and diagnosing diseases associated with Luey may be supplanted by new technology from the Company. It is a very exciting time to represent
Pathobiotek Diagnostics."
OTC Financial Network, a division of National Financial Communications Corp., is a financial communications and investor relations firm specializing in micro-cap
companies.
Pathobiotek Diagnostics Inc. is a product development and technology licensing company, whose current primary objective is the development, licensing and sale of
definitive diagnostics for diseases associated with the human microorganism, Luey. The Company's products find value in diagnostics, therapeutics, research,
technology and veterinary markets.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are
cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products,
increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks
detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. |
